Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01124552 | A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults | PHASE2 | COMPLETED | 180 | — | — | Apr 1, 2010 | Jul 1, 2010 | Jan 30, 2014 | 1 | United States |
The number of subjects who show improvement based on the investigator global assessment
| Arm | Type | Description |
|---|---|---|
| RT001 Botulinum toxin Type A (Dose A) | EXPERIMENTAL | RT001 (Botulinum toxin Type A) |
| RT001 Botulinum toxin type A (Dose B) | EXPERIMENTAL | RT001 (Botulinum Toxin Type A) |
| Dose C | OTHER | Vehicle Control |
| Dose D | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| RT001 Botulinum toxin type A (Dose A) | DRUG | RT001 Botulinum Toxin Type A (Dose A) |
| RT001 Botulinum Toxin Type A (Dose B) | DRUG | RT001 Botulinum Toxin Type A (Dose B) |
| Vehicle | OTHER | Vehicle Control |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: * Written informed consent including authorization to release health information * Female or male, 18 to 65 years of age and in good general health * Willing and able to follow study instructions and likely to complete all study requirements * Moderate to severe lateral canthal ...